Dilip Shanghvi, Managing Director, Sun Pharma
said, “We are excited by the robust pre-clinical data for GL0034 and believe that it has significant potential. We look forward to validating this data in human clinical trials.” Sun Pharma
is planning to initiate Phase-1 clinical trials for GL0034 by Q3FY21.
The pre-clinical data for GL0034 was recently presented at the American Diabetes Association (ADA) Virtual 80th Scientific Sessions. GL0034 has been developed internally by Sun Pharma’s High Impact Innovations – Sustainable Health Solutions (HISHS) Discovery Team.
In the animal trials, the performance of the NCE was assessed in mice. The NCE demonstrated outcomes of various diabetes parameters like glucose reduction, decrease in HbA1c (an important market for clinical efficacy), augmented insulin secretion, lowering of glucagon level and a marked and meaningful reduction in triglyceride levels, the company claimed.
Yet another important feature in diabetes treatment is weight management. GL0034 induced a larger body weight reduction.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.